sNDA and sBLA Drug Pipeline Report – 2H 2025

IPD Analytics has released its sNDA and sBLA Drug Pipeline Report – 2H 2025, featuring analyses on 17 key drugs poised for potential FDA approval for new or expanded indications over the next 6 months. For each product in the report, our experts include a clinical summary, expected place in therapy, and comparative pricing insights.

Complete with a timeline of upcoming PDUFA dates for select drugs with sBLA and sNDA submissions, the report helps payers track these approvals and proactively prepare for P&T committee reviews, update coverage policies, and assess any necessary adjustments to management strategies.